PENTASA Drug Patent Profile

When do Pentasa patents expire, and what generic alternatives are available?

Pentasa is a drug marketed by Takeda Pharms Usa and is included in one NDA.

The generic ingredient in PENTASA is mesalamine. There are twenty-eight drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pentasa

A generic version of PENTASA was approved as mesalamine by PADAGIS ISRAEL on September 17^th, 2004.

Summary for PENTASA

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for PENTASA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	PENTASA	mesalamine	CAPSULE, EXTENDED RELEASE;ORAL	020049-001	May 10, 1993	AB	RX	Yes	No
Takeda Pharms Usa	PENTASA	mesalamine	CAPSULE, EXTENDED RELEASE;ORAL	020049-002	Jul 8, 2004	AB	RX	Yes	Yes

International Patents for PENTASA

See the table below for patents covering PENTASA around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	S57500432
World Intellectual Property Organization (WIPO)	8102671

Last updated: February 5, 2026

What is PENTASA?

PENTASA is the brand name for mesalamine (also known as 5-aminosalicylic acid), used primarily to treat inflammatory bowel diseases (IBD), specifically ulcerative colitis. Marketed by Thermo Fisher Scientific under its generic form or by Alfasigma in some regions, PENTASA is an oral medication designed to deliver localized anti-inflammatory effects within the colon.

What are the key investment considerations for PENTASA?

Investment in PENTASA revolves around its market position, patent status, regulatory landscape, competitive environment, and pipeline developments.

Market Position and Demand Dynamics

PENTASA sustains steady demand driven by ulcerative colitis prevalence, which globally affects approximately 0.25% of the population. In the United States, about 900,000 individuals are affected. The chronic nature of ulcerative colitis requires long-term medication adherence, supporting consistent sales.

In Europe and Asia, increasing diagnosis rates and improved access to healthcare expand markets. PENTASA's differentiated formulation offers targeted delivery, which confers clinical benefits, favoring patient adherence.

Competitive Landscape

Major competitors include:

• Asacol (mesalamine formulations)
• Lialda (mesalamine formulations)
• Generic formulations from multiple manufacturers

The landscape is characterized by patent expirations, leading to rising generics competition, affecting gross margins.

Patent and Exclusivity Status

PENTASA’s original formulation has lost patent protection in most jurisdictions. In the U.S., the original patent expired in 2014, with some secondary patents expiring around 2019. In Europe, patent expiration occurred between 2016-2018. This has resulted in increased generic competition, exerting downward pressure on prices.

Regulatory Environment

Regulatory approval processes impact market entry and line extensions. PENTASA’s original approval was granted by the FDA in 1992 and EMA approvals around the same period. New formulations or delivery methods could secure orphan or new drug status, providing market exclusivity.

Pipeline and Formulation Developments

Some companies are exploring extended-release formulations or combination therapies to improve efficacy and reduce dosing frequency. Such innovations could re-establish market differentiation and extend product lifecycle.

Manufacturing and Cost Considerations

Generic manufacturing reduces costs but requires significant scale and compliance with quality standards. Supply chain stability and raw material sourcing influence profitability.

What are the financial fundamentals?

Revenue and Market Share

In 2022, the global market for mesalamine formulations was valued around USD 1.2 billion, with PENTASA representing approximately 25-30%. Post patent expiry, sales have declined marginally; however, the product maintains a significant share due to brand loyalty and formulation advantages.

Pricing Trends

Generic competition has led to reduced unit prices, with retail prices decreasing by approximately 40% over five years. Volume sales partly offset the margin declines.

Profitability and Margins

Gross margins in generic drug sales typically hover around 50-60%, but with increased competition, net margins for PENTASA products have compressed to approximately 20-25%.

Investment Risks and Opportunities

Risks include competitive erosion, pricing pressure, and regulatory hurdles. Opportunities lie in formulation innovation, pipeline development, and expanding into new markets.

How does PENTASA compare to similar treatments?

Aspect	PENTASA	Asacol	Lialda	Generic Mesalamine
Delivery Method	Dosage form for colon	Controlled-release tablets	Once-daily tablets	Varies
Patent Status	Expired (most markets)	Patents in force (some markets)	Patents expire 2024	None (post-expiry)
Market Share	~25-30% (oral mesalamine)	Leading in controlled-release	Growing segment	Declining due to generics
Price Point	Moderate	Premium	Premium	Low

What is the outlook for PENTASA's investment fundamentals?

Demand stability persists for ulcerative colitis treatments. Patent expiries and generic competition put sustained pressure on pricing. Innovation in formulations offers potential to regain margins and extend product life.

Investors should monitor pipeline development, regulatory changes, and shifts in market share. Geographic expansion into emerging markets presents growth avenues, provided regulatory challenges are addressed.

Key Takeaways

• PENTASA has a long-standing market presence, with stable demand in ulcerative colitis treatment.
• Patent expiries have increased generics, lowering prices and margins.
• Market entry barriers for new entrants are low given existing generic options.
• Innovation in delivery mechanisms or combination therapies could offer future differentiation.
• Market expansion into lower-income regions is constrained by regulatory and reimbursement hurdles but remains a potential growth driver.

FAQs

1. How does patent expiration impact PENTASA’s market exclusivity?
Patent expiration allows generic manufacturers to produce and sell equivalent formulations, leading to increased competition and lower prices, which can reduce PENTASA’s market share and margins.

2. Are there ongoing clinical trials or formulations that could revive PENTASA’s market position?
While formulations like extended-release or combination therapies are under investigation, none have received regulatory approval yet. Successful development could re-establish clinical and market differentiation.

3. How significant is the generic market penetration for PENTASA?
Post-patent expiry, generic versions comprise an increasing share, accounting for over 70% of the total mesalamine market in some regions, exerting downward pressure on prices.

4. What regulatory strategies could extend PENTASA’s lifecycle?
Formulation patents, new delivery systems, or approval for novel indications may provide exclusivity periods, delaying generic competition.

5. What are the growth opportunities in emerging markets for PENTASA?
Expanding into regions like China and India offers potential, contingent on regulatory approvals and reimbursement structures aligning with local healthcare systems.

---

Sources:

1. Market research reports on inflammatory bowel disease therapeutics (2022).
2. FDA and EMA patent expiration timelines for mesalamine products.
3. Industry analyses of generic drug market trends.
4. Clinical trial databases for mesalamine formulations.
5. WHO data on ulcerative colitis prevalence.